At September 8, an extraordinary meeting took place in Tallinn that was

attended  by shareholders of the Tallinn Pharmaceutical Plant, which is

affiliated  to Grindeks and at which it was planned to ratify the share

takeover offer made by Grindeks.



At  an  extraordinary  meeting  of shareholders, it was not possible to

convene  the  95%  of  Tallinn  Pharmaceutical  Plant shareholder votes

required  in  order  to  vote  on the share takeover offer made to this

company.



Eleven  shareholders  participated  in  the  extraordinary  meeting  of

Tallinn Pharmaceutical Plant shareholders who possessed 1,171,445 votes

that  together  made  up  93.72%  of the Tallinn Pharmaceutical Plant's

share  capital.  A  shareholders' meeting cannot make decisions if less

than 95% of available votes are represented therein.



As  Grindeks' Chairman of the Board, Valdis Jākobsons pointed out: "The

large  number  of  small  shareholders  proved  to  be  an  obstacle to

attaining  a  sufficient quorum of shareholders. Grindeks will continue

to   purchase  shares  in  accordance  with  procedures  prescribed  in

legislation."



At   present,   Grindeks   owns   1,168   276  or  93.46%  the  Tallinn

Pharmaceutical Plant's shares.



Information prepared by:

Janis  Romanovskis,  Finance  and  Administrative  Director of the PJSC

Grindeks.

Tel.: 7 083 250, 9 226767

e-mail: janis_romanovskis@grindeks.lv